TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30645028

Group type: EXPERIMENTAL
Intervention: LYR-210
Number of subjects: 20
Study: 30645176

Group type: EXPERIMENTAL
Intervention: Dietary feeding pattern during short-term bed rest
Number of subjects: 20
Study: 30646370

Group type: EXPERIMENTAL
Intervention: Patient-centered education bundle intervention
Number of subjects: 19652

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 19652
Study: 30646375

Group type: EXPERIMENTAL
Intervention: Return to work within 12 months after acute myocardial infarction
Number of subjects: 1566

Group type: EXPERIMENTAL
Intervention: Reasons for not returning to work
Number of subjects: 1566

Group type: EXPERIMENTAL
Intervention: Factors associated with returning to work
Number of subjects: 1566
Study: 30646425

Group type: EXPERIMENTAL
Intervention: Cataract surgery at ages 27 and 36 years for patients 1 and 2 respectively
Number of subjects: 3
Study: 30646872

Group type: EXPERIMENTAL
Intervention: Bernese Pain Scale for Neonates (BPSN)
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Heart rate measurement
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Gestational age (GA)
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Modified BPSN
Number of subjects: 154
Study: 30646942

Group type: EXPERIMENTAL
Intervention: SNP rs1004819 located on IL23R
Number of subjects: 645

Group type: EXPERIMENTAL
Intervention: SNP rs27434 located on ERAP1
Number of subjects: 645

Group type: EXPERIMENTAL
Intervention: Haplotype CCT of ERAP1
Number of subjects: 645

Group type: EXPERIMENTAL
Intervention: IL23R locus
Number of subjects: 645

Group type: COMPARATOR
Intervention: BASDAI, ASDAS-CRP, CRP, Berlin MRI score
Number of subjects: 645
Study: 30647051

Group type: COMPARATOR
Intervention: Moderate risk group (n=1663)
Number of subjects: 4957

Group type: COMPARATOR
Intervention: High risk group (n=144)
Number of subjects: 4957
Study: 30647082

Group type: EXPERIMENTAL
Intervention: Anti-PD-1 therapy
Number of subjects: 0
Study: 30648126

Group type: EXPERIMENTAL
Intervention: Dalbavancin (1500 mg IV on days 1 and 8)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard of care (SOC) for osteomyelitis (oral or IV) per investigator judgment for 4-6 weeks
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Dalbavancin
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard of care (SOC)
Number of subjects: 80
Study: 30648632

Group type: EXPERIMENTAL
Intervention: Sunitinib 50 mg/day individualized schedule
Number of subjects: 117
Study: 30648932

Group type: EXPERIMENTAL
Intervention: PCV13 followed by PPSV23 or PCV13 1 year later
Number of subjects: 962

Group type: COMPARATOR
Intervention: PPSV23 followed by PCV13 1 year later
Number of subjects: 962

Group type: EXPERIMENTAL
Intervention: PCV13 (first dose)
Number of subjects: 962
Study: 30649177

Group type: EXPERIMENTAL
Intervention: Onclarity HPV assay
Number of subjects: 33858

Group type: COMPARATOR
Intervention: Hybrid Capture 2
Number of subjects: 33858
Study: 30649404

Group type: EXPERIMENTAL
Intervention: Progesterone (P4) exposure during ovulatory cycles with normal or short luteal phase lengths
Number of subjects: 23

Group type: COMPARATOR
Intervention: Anovulatory cycles without P4 or Pd exposure
Number of subjects: 23
Study: 30649445

Group type: EXPERIMENTAL
Intervention: Grading scale (TRANSSPHER grade) based on preoperative MRI characteristics
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Validation cohort using the grading scale (TRANSSPHER grade)
Number of subjects: 222
Study: 30649524

Group type: EXPERIMENTAL
Intervention: TCZ-SC monotherapy + GC (5 mg/day)
Number of subjects: 1804

Group type: EXPERIMENTAL
Intervention: TCZ-SC monotherapy without GC
Number of subjects: 1804

Group type: EXPERIMENTAL
Intervention: TCZ-SC combination therapy + GC (5 mg/day)
Number of subjects: 1804

Group type: EXPERIMENTAL
Intervention: TCZ-SC combination therapy without GC
Number of subjects: 1804

Group type: EXPERIMENTAL
Intervention: All treatment subgroups (TCZ-SC with or without GC)
Number of subjects: 1804
Study: 30650259

Group type: EXPERIMENTAL
Intervention: Plazomicin (15 mg/kg administered by 30-minute intravenous infusion)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Plazomicin (20 mg/kg administered by 30-minute intravenous infusion)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56

Group type: COMPARATOR
Intervention: Oral moxifloxacin (400 mg)
Number of subjects: 56
Study: 30651126

Group type: EXPERIMENTAL
Intervention: Avelumab (10 mg/kg)
Number of subjects: 51
Study: 30651141

Group type: EXPERIMENTAL
Intervention: mRSS improvement at 12 months
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: mRSS MCID improvement criteria met
Number of subjects: 0
Study: 30651193

Group type: EXPERIMENTAL
Intervention: Higher DII scores (pro-inflammatory diet) in the SUN cohort
Number of subjects: 25356

Group type: EXPERIMENTAL
Intervention: Higher DII scores (pro-inflammatory diet) in the PREDIMED cohort
Number of subjects: 25356

Group type: EXPERIMENTAL
Intervention: Meta-analysis of 12 cohorts including SUN and PREDIMED
Number of subjects: 25356
Study: 30651576

Group type: EXPERIMENTAL
Intervention: Higher energy expenditure (EE)
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: Cognitive restraint
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: Disinhibition
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: Adjusted 24-h EE in Native Americans
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: Disinhibition in Native Americans
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: Higher 24-h EE
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: Greater 24-h EE
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: Higher 24-h EE in non-Native Americans
Number of subjects: 307
Study: 30651747

Group type: EXPERIMENTAL
Intervention: VD deficient (VDD)
Number of subjects: 2641

Group type: EXPERIMENTAL
Intervention: VD insufficient (VDI)
Number of subjects: 2641

Group type: EXPERIMENTAL
Intervention: VD sufficient (VDS)
Number of subjects: 2641
Study: 30652145

Group type: EXPERIMENTAL
Intervention: Prophylactic IVC filters
Number of subjects: 104
Study: 30653209

Group type: EXPERIMENTAL
Intervention: MRI before surgery
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: MRI findings
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: Patient preference
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: Positive margins after attempted WLE
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: Positive genetic test results
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: Contraindication to radiotherapy
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: WLE after MRI
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: Radiotherapy guided by DCIS score
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: DCIS score
Number of subjects: 339
Study: 30653530

Group type: EXPERIMENTAL
Intervention: Substance use
Number of subjects: 906

Group type: EXPERIMENTAL
Intervention: Gang activity
Number of subjects: 906

Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 906

Group type: EXPERIMENTAL
Intervention: Higher stress levels
Number of subjects: 906

Group type: EXPERIMENTAL
Intervention: Lower education levels
Number of subjects: 906

Group type: EXPERIMENTAL
Intervention: Better community infrastructure
Number of subjects: 906

Group type: EXPERIMENTAL
Intervention: More recently established communities with recent immigrants
Number of subjects: 906
Study: 30653786

Group type: EXPERIMENTAL
Intervention: Obese females
Number of subjects: 56

Group type: COMPARATOR
Intervention: Normal-weight controls
Number of subjects: 56
Study: 30653818

Group type: EXPERIMENTAL
Intervention: Bladder EpiCheck test
Number of subjects: 440
Study: 30654137

Group type: EXPERIMENTAL
Intervention: Plerixafor (240 μg/kg s.c.) administered before conditioning chemotherapy (fludarabine and busulfan) for 1 to 4 days depending on the cohort.
Number of subjects: 12
Study: 30654246

Group type: EXPERIMENTAL
Intervention: Alemtuzumab with enhanced infusion-associated reaction (IAR) prophylaxis
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Alemtuzumab with enhanced IAR prophylaxis
Number of subjects: 58
Study: 30654810

Group type: EXPERIMENTAL
Intervention: Cadence thresholds of 100 steps/min for moderate intensity (3 METs)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Cadence thresholds of 130 steps/min for vigorous intensity (6 METs)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Optimal cadence thresholds using regression model
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Optimal cadence thresholds using ROC models
Number of subjects: 76
Study: 30655164

Group type: EXPERIMENTAL
Intervention: TCR-modified T cells
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TCR gene-modified cells
Number of subjects: 0
Study: 30655366

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 30655385

Group type: EXPERIMENTAL
Intervention: Children with high-risk HLA genotypes (specific details not provided)
Number of subjects: 0
Study: 30655690

Group type: EXPERIMENTAL
Intervention: active tDCS and active EIMS (a-tDCS/a-EIMS)
Number of subjects: 60

Group type: COMPARATOR
Intervention: sham tDCS and sham EIMS (s-tDCS/s-EIMS)
Number of subjects: 60

Group type: COMPARATOR
Intervention: active tDCS and sham EIMS (a-tDCS/s-EIMS)
Number of subjects: 60

Group type: COMPARATOR
Intervention: sham tDCS and active EIMS (s-tDCS/a-EIMS)
Number of subjects: 60
Study: 30656132

Group type: EXPERIMENTAL
Intervention: Physically active academic lessons
Number of subjects: 447
Study: 30656154

Group type: EXPERIMENTAL
Intervention: Functional Movement Screen (FMS) scores
Number of subjects: 51
Study: 30656241

Group type: EXPERIMENTAL
Intervention: Wearable sensor device for detection of atrial fibrillation
Number of subjects: 2659

Group type: COMPARATOR
Intervention: Email invitation
Number of subjects: 2659

Group type: EXPERIMENTAL
Intervention: Five-step outreach process (three short personalized emails and two direct mailers)
Number of subjects: 2659

Group type: EXPERIMENTAL
Intervention: Messaging highlighting access to new technology
Number of subjects: 2659
Study: 30656283

Group type: EXPERIMENTAL
Intervention: Prophylactic rFIXFc with a ≥14-day dosing interval
Number of subjects: 22
Study: 30656479

Group type: EXPERIMENTAL
Intervention: EIT-guided PEEP titration
Number of subjects: 24

Group type: COMPARATOR
Intervention: Pressure-volume curve-guided PEEP titration
Number of subjects: 24
Study: 30656602

Group type: EXPERIMENTAL
Intervention: Reappraisal
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Acceptance
Number of subjects: 35
Study: 30657083

Group type: EXPERIMENTAL
Intervention: Nurses with LBP
Number of subjects: 120

Group type: COMPARATOR
Intervention: Nurses without LBP
Number of subjects: 120
Study: 30657223

Group type: EXPERIMENTAL
Intervention: Aflibercept (4 mg/kg) plus FOLFIRI administered every 2 weeks
Number of subjects: 62
Study: 30657405

Group type: EXPERIMENTAL
Intervention: Optimal PVP timing (194 patients)
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: Early PVP timing (52 patients)
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: Late PVP timing (45 patients)
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: Overall population (291 patients)
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: Computer-aided quality-control system
Number of subjects: 291
Study: 30657642

Group type: EXPERIMENTAL
Intervention: PrEP
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: ART
Number of subjects: 93
Study: 30657884

Group type: EXPERIMENTAL
Intervention: Normal BMI group (<25.0 kg/m2)
Number of subjects: 1568

Group type: EXPERIMENTAL
Intervention: Overweight BMI group (25.0-29.9 kg/m2)
Number of subjects: 1568

Group type: EXPERIMENTAL
Intervention: Obesity BMI group (≥30.0 kg/m2)
Number of subjects: 1568

Group type: EXPERIMENTAL
Intervention: Subjects in the same BMI group at CCTA1 and CCTA2 (1424 subjects, 90.8%)
Number of subjects: 1568

Group type: EXPERIMENTAL
Intervention: Subjects with change in BMI group at CCTA2 (144 subjects, 9.2%)
Number of subjects: 1568

Group type: EXPERIMENTAL
Intervention: Percent change of BMI
Number of subjects: 1568

Group type: EXPERIMENTAL
Intervention: Male gender
Number of subjects: 1568

Group type: EXPERIMENTAL
Intervention: Baseline plaque volume
Number of subjects: 1568

Group type: EXPERIMENTAL
Intervention: Baseline overweight or obesity
Number of subjects: 1568
Study: 30657914

Group type: EXPERIMENTAL
Intervention: Dairy intake (100 g/d increase)
Number of subjects: 6671

Group type: EXPERIMENTAL
Intervention: Fruit and vegetable intake (100 g/d increase)
Number of subjects: 6671

Group type: EXPERIMENTAL
Intervention: Fruit and vegetable intake
Number of subjects: 6671

Group type: EXPERIMENTAL
Intervention: Sweet snacks intake
Number of subjects: 6671

Group type: EXPERIMENTAL
Intervention: Fish intake
Number of subjects: 6671

Group type: EXPERIMENTAL
Intervention: Plant-based fat and oil intake
Number of subjects: 6671
Study: 30657926

Group type: EXPERIMENTAL
Intervention: Varenicline for 12 weeks and six guideline-based smoking cessation counseling sessions
Number of subjects: 449

Group type: EXPERIMENTAL
Intervention: Home ownership (yes/no)
Number of subjects: 449

Group type: EXPERIMENTAL
Intervention: Study visits completed (range=0-6)
Number of subjects: 449

Group type: EXPERIMENTAL
Intervention: Income (household member/$1000)
Number of subjects: 449

Group type: EXPERIMENTAL
Intervention: Plasma cotinine (per 1 ng/mL)
Number of subjects: 449

Group type: EXPERIMENTAL
Intervention: Neighborhood problems (range=10-30)
Number of subjects: 449
Study: 30658128

Group type: EXPERIMENTAL
Intervention: 9-valent HPV vaccine
Number of subjects: 145
Study: 30658648

Group type: EXPERIMENTAL
Intervention: Interprofessional clinical training
Number of subjects: 195

Group type: COMPARATOR
Intervention: Conventional clinical training
Number of subjects: 195
Study: 30658992

Group type: EXPERIMENTAL
Intervention: Pediatric ALL regimen administered by adult treatment teams
Number of subjects: 295

Group type: COMPARATOR
Intervention: Historical control
Number of subjects: 295
Study: 30659040

Group type: EXPERIMENTAL
Intervention: Low-dose chest CT (LDCT) screening
Number of subjects: 2537
Study: 30659076

Group type: EXPERIMENTAL
Intervention: Urban population
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Town population
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Periurban villages (PUVs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Abdominal obesity
Number of subjects: 0
Study: 30659892

Group type: EXPERIMENTAL
Intervention: Intraoperative radiotherapy (20-40 Gy)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control (standard therapy)
Number of subjects: 15
Study: 30660511

Group type: EXPERIMENTAL
Intervention: Nivolumab (240 mg every 2 weeks) plus ipilimumab (1 mg/kg every 6 weeks up to four times)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Nivolumab plus ipilimumab
Number of subjects: 34
Study: 30660617

Group type: EXPERIMENTAL
Intervention: Grazoprevir 100 mg plus Elbasvir 50 mg (8 weeks treatment)
Number of subjects: 80
Study: 30661037

Group type: EXPERIMENTAL
Intervention: High educational attainment (senior high school, college or postgraduate degree)
Number of subjects: 3369

Group type: COMPARATOR
Intervention: Low educational attainment (primary school or illiterate)
Number of subjects: 3369
Study: 30661097

Group type: EXPERIMENTAL
Intervention: Dabrafenib and trametinib (CombiDT)
Number of subjects: 34
Study: 30661177

Group type: EXPERIMENTAL
Intervention: Danvatirsen 3 mg/kg
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Danvatirsen 200 mg flat dosing
Number of subjects: 126

Group type: COMPARATOR
Intervention: Flat dosing regimen
Number of subjects: 126
Study: 30661197

Group type: EXPERIMENTAL
Intervention: Adalimumab treatment
Number of subjects: 106
Study: 30661491

Group type: EXPERIMENTAL
Intervention: Negative remodeling
Number of subjects: 30

Group type: COMPARATOR
Intervention: Nonnegative remodeling
Number of subjects: 30
Study: 30662504

Group type: EXPERIMENTAL
Intervention: Deep Oscillation (DO)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 8
Study: 30662958

Group type: EXPERIMENTAL
Intervention: Individual rewards
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mixed rewards
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no rewards)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Individual rewards for diabetes management, details on dosage and duration not available.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mixed rewards for diabetes management, details on dosage and duration not available.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified, details on intervention not available.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 30663068

Group type: EXPERIMENTAL
Intervention: Patient Decision Aid (PDA)
Number of subjects: 0
Study: 30663107

Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg b.d.
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg b.d.
Number of subjects: 150
Study: 30663346

Group type: EXPERIMENTAL
Intervention: Fecal microbiota of patients with acute appendicitis
Number of subjects: 99

Group type: COMPARATOR
Intervention: Fecal microbiota of healthy controls
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Discriminant analyses
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Appendiceal microbiota analysis
Number of subjects: 99
Study: 30663562

Group type: EXPERIMENTAL
Intervention: Lomitapide
Number of subjects: 0
Study: 30663898

Group type: EXPERIMENTAL
Intervention: Sedentary lifestyle
Number of subjects: 602
Study: 30663902

Group type: EXPERIMENTAL
Intervention: Lunasin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 30664011

Group type: EXPERIMENTAL
Intervention: ΔPCO2 measured at 2 hours after ICU admission
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: Blood lactate concentration measured at 2 hours after ICU admission
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: Central venous oxygen saturation measured at 2 hours after ICU admission
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: ΔPCO2 to arteriovenous oxygen content difference ratio
Number of subjects: 308
Study: 30664483

Group type: EXPERIMENTAL
Intervention: Ghya Bharari Ekatra intervention delivered in 6 weekly sessions by trained community educators; includes games, discussions, self-reflections, and skill-building exercises.
Number of subjects: 0
Study: 30664496

Group type: EXPERIMENTAL
Intervention: Chemotherapy with TheraSphere yttrium-90 (TARE)
Number of subjects: 420

Group type: COMPARATOR
Intervention: Chemotherapy alone (Control)
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Overall survival, time to symptomatic progression, objective response rate, disease control rate, quality-of-life assessment, and adverse events
Number of subjects: 420
Study: 30664526

Group type: EXPERIMENTAL
Intervention: Chronic critical illness (≥ 14 ICU days with persistent organ dysfunction)
Number of subjects: 173
Study: 30664564

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIg) 1 g/kg/dose infused at 3-5, 30, and 60 days post-hepatoportoenterostomy (HPE)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIg)
Number of subjects: 29
Study: 30664876

Group type: EXPERIMENTAL
Intervention: HDV-specific CD8 T cells
Number of subjects: 28
Study: 30665258

Group type: EXPERIMENTAL
Intervention: Tacrolimus granules
Number of subjects: 0
Study: 30665804

Group type: EXPERIMENTAL
Intervention: Device-detected sleep-disordered breathing (SDB) events
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: CIED-detected atrial high rate episodes (AHREs)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: CIED-detected or clinical ventricular arrhythmic events
Number of subjects: 600
Study: 30666472

Group type: EXPERIMENTAL
Intervention: PPG-RR (photoplethysmographic respiratory rate)
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: PPG-RR
Number of subjects: 201
Study: 30667281

Group type: EXPERIMENTAL
Intervention: Evidence-based acute treatments for ACS (including early dual antiplatelet therapy, heparins during hospitalization, reperfusion therapy for ST-segment-elevation myocardial infarction)
Number of subjects: 82196

Group type: EXPERIMENTAL
Intervention: Strategies for secondary prevention (including dual antiplatelet therapy, ACE inhibitors/ARBs, statins at discharge, smoking cessation, cardiac rehabilitation counseling)
Number of subjects: 82196

Group type: EXPERIMENTAL
Intervention: In-hospital mortality rate
Number of subjects: 82196

Group type: COMPARATOR
Intervention: In-hospital mortality in ST-segment-elevation myocardial infarction
Number of subjects: 82196

Group type: COMPARATOR
Intervention: In-hospital mortality in non-ST-segment elevation ACS
Number of subjects: 82196
Study: 30667348

Group type: EXPERIMENTAL
Intervention: Cessation of anticoagulation therapy after endovascular thrombus removal and stent placement
Number of subjects: 0
Study: 30668184

Group type: EXPERIMENTAL
Intervention: Black tea dressings
Number of subjects: 0
Study: 30668217

Group type: EXPERIMENTAL
Intervention: DTaP-IPV vaccine
Number of subjects: 639
Study: 30668695

Group type: EXPERIMENTAL
Intervention: Dolutegravir plus lamivudine
Number of subjects: 120
Study: 30668843

Group type: EXPERIMENTAL
Intervention: Early therapy (ET) - HIV-1-infected children
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Late therapy (LT) - HIV-1-infected children
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Non-response (NR) - HIV-1-infected children
Number of subjects: 46

Group type: COMPARATOR
Intervention: HIV-1-uninfected children (SR) - control group
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: HIV-1 Ab levels to p31 and p17
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: HIV-1 Ab levels to gp160 and gp41
Number of subjects: 46
Study: 30669161

Group type: EXPERIMENTAL
Intervention: EUS-guided radiofrequency ablation (RFA)
Number of subjects: 30
Study: 30669936

Group type: EXPERIMENTAL
Intervention: Patient-Reported Functional Scale-ICU (PRFS-ICU) assessment
Number of subjects: 20